Dr Vivak Parkash

All publications

Journal articles

• Faust SN, Haynes R, Jones CE, Staplin N, Whittaker E, Jaki T, Juszczak E, Spata E, Wan M, Bamford A , Dimitri P et al (2024) Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet Child & Adolescent Health, 8(3), 190-200. View this article in WRRO
• Abani O, Abbas A, Abbas F, Abbas J, Abbas K, Abbas M, Abbasi S, Abbass H, Abbott A, Abdallah N , Abdelaziz A et al (2023) Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet Diabetes & Endocrinology, 11(12), 905-914. View this article in WRRO
• Senarathne S, Ranasinghe S, Kahawita I, Somaratne V, Wickramasinghe A, Parkash V, Lacey C, Kaye P & Layton A (2023) GD03 Identifying core outcome domains and development of a cutaneous leishmaniasis core outcome measure for use in clinical practice and trials. British Journal of Dermatology, 188(Supplement_4).
• Abani O, Abbas A, Abbas F, Abbas J, Abbas K, Abbas M, Abbasi S, Abbass H, Abbott A, Abbott A , Abdallah N et al (2023) Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet, 401(10387), 1499-1507. View this article in WRRO
• Parkash V, Laundy N & Durojaiye OC (2023) Outpatient parenteral antimicrobial therapy for leishmaniasis: 13 years’ experience at a large UK infectious diseases centre. Transactions of The Royal Society of Tropical Medicine and Hygiene, 117(6), 473-475.
• Parkash V, Ashwin H, Jones G, Sadlova J, Vojtkova B, Jaffe C, Volf P, Layton A, Kaye P & Lacey C (2022) 37 Pathway to a controlled human infection model for Leishmania major. Clinical Infection in Practice, 15, 100198-100198.
• RECOVERY Collaborative Group T (2022) Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial and updated meta-analysis. The Lancet, 400(10349), 359-368. View this article in WRRO
• Kaye PM, Mohan S, Mantel C, Malhame M, Revill P, Le Rutte E, Parkash V, Layton AM, Lacey CJN & Malvolti S (2021) Overcoming roadblocks in the development of vaccines for leishmaniasis. Expert Review of Vaccines, 20(11), 1419-1430.
• Parkash V, Kaye PM, Layton AM & Lacey CJ (2021) Vaccines against leishmaniasis: using controlled human infection models to accelerate development. Expert Review of Vaccines, 20(11), 1407-1418.
• Parkash V, Jones G, Martin N, Steigmann M, Greensted E, Kaye P, Layton AM & Lacey CJ (2021) Assessing public perception of a sand fly biting study on the pathway to a controlled human infection model for cutaneous leishmaniasis. Research Involvement and Engagement, 7(1).
• Shahin Y, Rajaram S, Parkash V, Wild J, Kiely DG & Swift A (2021) Patterns of thromboembolic pulmonary vascular disease in COVID-19. Pulmonary Circulation, 11(1). View this article in WRRO
• Keeley AJ, Parkash V, Tunbridge A, Greig J, Collini P, McKane W & Tattersall RS (2020) Anakinra in the treatment of protracted paradoxical inflammatory reactions in HIV-associated tuberculosis in the United Kingdom : a report of two cases. International Journal of STD & AIDS, 31(8), 808-812. View this article in WRRO
• Keeley AJ, Parkash V, Tunbridge A, Greig J, Collini P & Tattersall RS (2020) P24 The successful use of anakinra to control protracted immune reconstitution inflammatory syndrome in HIV associated tuberculosis: a report of two cases. Rheumatology, 59(Supplement_2).
• Parkash V, Woods K, Kafetzopoulou L, Osborne J, Aarons E & Cartwright K (2019) West Nile Virus Infection in Travelers Returning to United Kingdom from South Africa. Emerging Infectious Diseases, 25(2), 367-369.
• Parkash V, Mudhar HS, Wagner BE, Raoult D, Batty R, Lepidi H, Burke J, Collini P & de Silva T (2016) Bilateral Ocular Myositis Associated with Whipple's Disease. Ocular Oncology and Pathology, 3, 17-21. View this article in WRRO
• Ranasinghe S, Senarathne S, Somaratne V, Lacey CJN, Jayakody S, Wickramasinghe A, Kahawita I, Goto H, Chatterjee M, Lindoso JAL , Parkash V et al () Development of a Core Outcome Measure Instrument; "LeishCOM_LCL”, for Localised Cutaneous Leishmaniasis. PLOS Neglected Tropical Diseases, 18(8), e0012393-e0012393.
• Parkash V, Ashwin H, Dey S, Sadlova J, Vojtkova B, Van Bocxlaer K, Wiggins R, Thompson D, Dey NS, Jaffe CL , Schwartz E et al () Safety and reactogenicity of a controlled human infection model of sand fly-transmitted cutaneous leishmaniasis. Nature Medicine.
• Parkash V, Ashwin H, Sadlova J, Vojtkova B, Jones G, Martin N, Greensted E, Allgar V, Kamhawi S, Valenzuela JG , Layton AM et al () A clinical study to optimise a sand fly biting protocol for use in a controlled human infection model of cutaneous leishmaniasis (the FLYBITE study). Wellcome Open Research, 6, 168-168.
• Ashwin H, Sadlova J, Vojtkova B, Becvar T, Lypaczewski P, Schwartz E, Greensted E, Van Bocxlaer K, Pasin M, Lipinski KS , Parkash V et al () Characterization of a new Leishmania major strain for use in a controlled human infection model. Nature Communications, 12(1).

Chapters

• Kaye PM, Parkash V, Layton AM & Lacey CJN (2023) The Utility of a Controlled Human Infection Model for Developing Leishmaniasis Vaccines, Vaccines for Neglected Pathogens: Strategies, Achievements and Challenges (pp. 263-279). Springer International Publishing

Conference proceedings papers

• Keeley AJ, Parkash V, Tunbridge A, Greig J, Collini P & Tattersall RS (2020) THE SUCCESSFUL USE OF ANAKINRA TO CONTROL PROTRACTED IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN HIV ASSOCIATED TUBERCULOSIS: A REPORT OF TWO CASES. RHEUMATOLOGY, Vol. 59
• Parkash V & Tunbridge A (2017) A case of tuberculosis-associated immune reconstitution inflammatory syndrome (IRIS) managed with an interleukin-1 receptor antagonist. HIV MEDICINE, Vol. 18 (pp 30-31)
• Garner A, Parkash V & Gupta N (2014) Etoricoxib-induced drug eruption causing penile ulceration: A case report. HIV MEDICINE, Vol. 15 (pp 158-159)
• Parkash V, Garner A & Gupta N (2014) Evaluation of PEPSE use in a district general hospital genitourinary medicine department. HIV MEDICINE, Vol. 15 (pp 148-148)

Preprints

• Ranasinghe S, Senarathne S, Somaratne V, Lacey CJN, Jayakody S, Wickramasinghe A, Kahawita I, Goto H, Chatterjee M, Lindoso JAL , Parkash V et al (2024) Development of a Core Outcome Measure Instrument; “LeishCOM_LCL”, for Localised Cutaneous Leishmaniasis, Cold Spring Harbor Laboratory.
• Parkash V, Ashwin H, Dey S, Sadlova J, Vojtkova B, Bocxlaer KV, Wiggins R, Thompson D, Dey NS, Jaffe CL , Schwartz E et al (2024) Safety, effectiveness, and skin immune response in a controlled human infection model of sand fly transmitted cutaneous leishmaniasis, Cold Spring Harbor Laboratory.
• Ashwin H, Sadlova J, Vojtkova B, Becvar T, Lypaczewski P, Schwartz E, Greensted E, Van Bocxlaer K, Pasin M, Lipinski KS , Parkash V et al (2020) Characterization of a newLeishmania majorisolate for use in a controlled human infection model, Cold Spring Harbor Laboratory.